Validation of MYC-driven drug responses.

Slides:

Advertisements

Similar presentations

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Advertisements

IDH1 mutant glioma cells are sensitive to TMZ

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

DNAPKcs is required for DNA repair in the presence of androgen.

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

AKT dependence of ovarian cancer cell lines.

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

Volume 22, Issue 2, Pages (February 2015)

Volume 20, Issue 4, Pages (October 2011)

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. Confirmation of synergy and cytotoxicity of genotype-selective drug pairs. A,

AKT2, but not AKT1, is required for regulating survival of PTEN-deficient prostate tumor spheroids. AKT2, but not AKT1, is required for regulating survival.

AML cells display differential sensitivity to inhibition of IKBKE and TBK1. AML cells display differential sensitivity to inhibition of IKBKE and TBK1.

CEP55 is a downstream effector of MAPK signaling

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

Predicting drug sensitivity from proteomic (RPPA) data clusters.

Inhibition of lung cancer cell proliferation and viability by CYT387.

GR cells are dependent upon sustained CDC25C signaling as pharmacologic or genetic inhibition of CDC25C induce synthetic lethality. GR cells are dependent.

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Activity of SW480 qHTS runs and podophyllotoxin titration–response profiles of from library and control samples. Activity of SW480 qHTS runs and podophyllotoxin.

PTENP1 sensitizes renal cancer cells to chemotherapy.

Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

Inhibition of stress-associated MAPK signaling attenuates SASP expression in CAFs. A, N-CAFs were treated with 100 nmol/L GEM plus DMSO or the above-listed.

Greater induction of apoptosis following EGFR TKI treatment correlates with higher basal BIM expression across a panel of EGFR-mutant lung cancers. Greater.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

MiR-200c is a PI3K–AKT signaling pathway regulator in CRC

Biological effects of BRAF silencing: growth curves of A375 (A) and ARO (B) cell lines in the absence or presence of doxycycline. Biological effects of.

Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma cells. Effect of GSK3β inhibition on cell survival and proliferation of glioblastoma.

FcRγ signaling regulates BTK activation and mediates PDAC growth.

Platinum-based chemotherapy increased TXNIP expression, and overexpression of TXNIP enhanced the effectiveness of this therapy. Platinum-based chemotherapy.

IGF-I partially protects Rh30 cells from apoptosis despite simultaneous inhibition of PI3K-Akt and MAP kinase pathways. IGF-I partially protects Rh30 cells.

by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.

Induction of apoptosis by statins in NB4 cells and NB4 variant cell lines. Induction of apoptosis by statins in NB4 cells and NB4 variant cell lines. A,

The effects of AZD1775 and olaparib on DNA damage response signaling.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Functional SLC6A3 in ccRCC cell lines KMRC3 and SNU-349, but not in conventional cell lines. Functional SLC6A3 in ccRCC cell lines KMRC3 and SNU-349, but.

Cell lines from hematologic cancers, including multiple myeloma (MM), AML, and DLBCL, exhibit a strong dependency on MCL1 for survival. Cell lines from.

Interaction of NHEJ and HR pathways in PCO cultures.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.

Effect of BCAA on the progression of cell cycle, expression of p21CIP1, and induction of apoptosis in HepG2 cells in the presence and absence of visfatin.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.

Global analysis of the chemical–genetic interaction map.

An isogenic cell line screen reveals genomic drivers of drug response.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

MYC and LYN are coexpressed and have interdependent clinical outcomes.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

Quercetin induces autophagy, blocks cell cycle and activation of ERK and JNK signaling pathways participates in the G1 arrest in P39 cells. Quercetin induces.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

EPHA2 inhibitors inhibit phosphorylation of AKT and ERK, arrest cell cycle at G0–G1, and induce apoptosis in both vemurafenib (VEM)-sensitive and VEM-resistant.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

NUAK1 overexpression correlates with tumor progression, lymph node infiltrates, and reduced overall survival (OS) in human colorectal cancer. NUAK1 overexpression.

A, Pharmacologically inhibiting protein tyrosine kinases significantly reduces the viability of ATRT cell lines as compared with control HEK 293 cells.

ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits migration. ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits.

I3C reduces the level of Cdc25A protein in breast cancer cells.

Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

Validation of MYC-driven drug responses. Validation of MYC-driven drug responses. A, volcano plot of MYC-driven drug responses identified in MCF10AMYC cells versus control. Drug responses with S ≥ 2 are highlighted. B, validation of relative growth rates of drug-treated MCF10APURO and MCF10AMYC cells compared with DMSO control in the presence of AKT–PI3K–MTOR pathway inhibitors as indicated in A. C, sensitivity to AKT inhibitor MK-2206 compared with MYC expression across a panel of 20 breast cancer cell lines separated into two equally sized groups to define sensitive and resistant lines with RNAseq data from ref. 54. D, validation of relative growth rates of drug-treated MCF10A lines with synthetic lethal hits in A. E, concentration–response of viability of isogenic cell lines to GSK3B inhibitor CHIR-99021. F, fraction of total cell population undergoing apoptosis in response to drug treatment for 24 hours as measured by Annexin V staining. G, levels of p-GSK3B Ser9 and total MYC after treatment of MCF10A cells for 18 hours. GAPDH is used as a loading control. Unless otherwise noted, drug concentrations are the near IC50 listed in Supplementary Table S2. ***, P < 0.001; **, P < 0.01. Maria M. Martins et al. Cancer Discov 2015;5:154-167 ©2015 by American Association for Cancer Research